Finance
Bayer sues Johnson & Johnson over marketing of prostate cancer drug
Published by Global Banking & Finance Review®
Posted on February 23, 2026
1 min readLast updated: February 23, 2026
Quick Summary
Bayer said it filed a New York lawsuit against Johnson & Johnson and Janssen Biotech tied to its Nubeqa prostate cancer drug. The brief Reuters update was datelined Berlin on Feb. 23.
NEW YORK, Feb 23 (Reuters) - Bayer sued Johnson & Johnson on Monday, accusing the rival drugmaker of falsely advertising a drug intended to treat prostate cancer.
According to a complaint filed in Manhattan federal court, Johnson & Johnson launched a false advertising campaign against Bayer's Nubeqa drug, in order to promote and demonstrate the alleged superiority of its own drug, Erleada.
Bayer is seeking triple damages, the recoupment of alleged ill-gotten profits, and an injunction to stop Johnson & Johnson's alleged false advertising.
Johnson & Johnson did not immediately respond to a request for comment.
(Reporting by Jonathan Stempel in New York; Additional reporting by Friederike Heine in Berlin; Editing by Tomasz Janowski and Chizu Nomiyama)
Key Takeaways
- •Bayer filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech.
- •The dispute concerns Bayer’s Nubeqa prostate cancer drug.
- •The brief update was reported from Berlin on Feb. 23.
- •Further details on the claims were not disclosed in the short report.
Frequently Asked Questions about Bayer sues Johnson & Johnson over marketing of prostate cancer drug
1What is the main topic?
Bayer has filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech. The case is related to Bayer’s Nubeqa prostate cancer drug.
2Who is being sued and where was the case filed?
Johnson & Johnson and Janssen Biotech are the defendants. The suit was filed in a New York court.
3What is Nubeqa and why is it relevant?
Nubeqa (darolutamide) is Bayer’s prostate cancer medication. The lawsuit is connected to this drug.
